Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 450 of 496 entries
View as:

A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00855894 Org: User:
Start: 03/31/09 End: 03/31/12 Due: 03/31/13

An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00097565 Org: User:
Start: 03/31/04 End: 03/31/14 Due: 03/31/15

Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00061178 Org: User:
Start: - End: - Due: -

A Study to Assess the Effect of Topical Recombinant Human Vascular Endothelial Growth Factor for Induction of Healing of Diabetic Foot Ulcers

Phase: N/A Priority: Normal
NCT ID: NCT00351767 Org: User:
Start: 01/31/06 End: - Due: -

A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)

Phase: N/A Priority: Normal
NCT ID: NCT00096954 Org: User:
Start: 02/28/06 End: 09/30/10 Due: 09/30/11

Cathflo Activase Pediatric Study

Phase: N/A Priority: Normal
NCT ID: NCT00307580 Org: User:
Start: 04/30/02 End: 05/31/03 Due: 05/31/04

Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980

Phase: N/A Priority: Normal
NCT ID: NCT01473316 Org: User:
Start: 11/30/11 End: 12/31/11 Due: 12/31/12

A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)

Phase: N/A Priority: Normal
NCT ID: NCT02486809 Org: User:
Start: 07/31/15 End: 10/31/15 Due: 10/31/16

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics

Phase: N/A Priority: Normal
NCT ID: NCT03162250 Org: User:
Start: 07/13/17 End: 01/15/20 Due: 01/15/21

Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01480310 Org: User:
Start: 12/31/11 End: 06/30/12 Due: 06/30/13

A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma

Phase: N/A Priority: Normal
NCT ID: NCT00109200 Org: User:
Start: 05/31/03 End: 09/30/03 Due: 09/30/04

A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria

Phase: N/A Priority: Normal
NCT ID: NCT05129423 Org: User:
Start: 07/31/22 End: 08/31/24 Due: 08/31/25

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

Phase: N/A Priority: Normal
NCT ID: NCT05968326 Org: User:
Start: 10/18/23 End: 12/27/29 Due: 12/27/30

A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Phase: N/A Priority: Normal
NCT ID: NCT03972709 Org: User:
Start: 06/03/19 End: 10/27/22 Due: 10/27/23

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Phase: N/A Priority: Normal
NCT ID: NCT00781612 Org: User:
Start: 10/16/08 End: 09/30/29 Due: 09/30/30

Study of Cobimetinib in Participants With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00467779 Org: User:
Start: 05/31/07 End: 04/30/14 Due: 04/30/15

Prospective Clinicogenomic Program

Phase: N/A Priority: Normal
NCT ID: NCT04180176 Org: User:
Start: 12/13/19 End: 11/30/23 Due: 11/30/24

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

Phase: N/A Priority: Normal
NCT ID: NCT01991184 Org: User:
Start: 12/16/13 End: 03/08/22 Due: 03/08/23

A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)

Phase: N/A Priority: Normal
NCT ID: NCT00473590 Org: User:
Start: 06/30/07 End: 11/30/09 Due: 11/30/10

A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01290549 Org: User:
Start: 03/22/11 End: 11/18/14 Due: 11/18/15

An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy

Phase: N/A Priority: Normal
NCT ID: NCT01602120 Org: User:
Start: 05/29/12 End: 02/09/18 Due: 02/09/19

A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)

Phase: N/A Priority: Normal
NCT ID: NCT00491738 Org: User:
Start: 08/31/07 End: - Due: -

An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study

Phase: N/A Priority: Normal
NCT ID: NCT00109057 Org: User:
Start: 02/28/98 End: 02/29/04 Due: 02/28/05

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

Phase: N/A Priority: Normal
NCT ID: NCT03858634 Org: User:
Start: 05/29/19 End: 06/08/20 Due: 06/08/21

An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01868893 Org: User:
Start: 08/31/13 End: 01/31/14 Due: 01/31/15